CAH Cardinal Health, Inc.
USHealthcareAs of 2026-08-24
Why CAH matters now
Cardinal Health, Inc. (CAH) is a US stock in Healthcare. The latest InvestLog snapshot shows $232.33 with +1.23% on the session and $54.41B in market capitalization; recent performance reads 1-month +10.68% and YTD +7.92%.
The latest financial table shown here is Q3 2026, with revenue of $60.94B, net income of $399.0M, and EPS of $1.69. Investors can compare that operating picture with valuation signals such as P/E 30.44 and FCF yield 8.5%.
InvestLog's latest related AI research is a Insider Sale note titled "Hollar Jason M. sells $29.4M of CAH". The latest indexable market news headline is "Reasons to Retain Cardinal Health Stock in Your Portfolio for Now" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $255.50; recent insider activity includes Hall Patricia Hemingway filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
30.44
PEG
1.13
P/B
-18.40
P/S
0.21
EV/EBITDA
18.81
DCF Value
$350.82
FCF Yield
8.5%
Div Yield
0.9%
Margins & Returns
Gross Margin
3.7%
Operating Margin
0.9%
Net Margin
0.6%
ROE
-55.7%
ROA
2.8%
ROIC
11.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $60.94B | $399.0M | $1.69 |
| Q2 2026 | $65.44B | $471.0M | $1.97 |
| Q1 2026 | $64.01B | $450.0M | $1.88 |
| Q4 2025 | $60.16B | $239.0M | $1.00 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$253.38
Target (Median)
$255.50
Target Range
$235.00 - $275.00
Trading Activity
Insider Trades
Related AI Research
Hollar Jason M. sells $29.4M of CAHHollar Jason M. 内部减持 卡地纳健康 (CAH) $29.4M
Cardinal Health (CAH) Chief Executive Officer Hollar Jason M. completed an open-market stock sale on August 19, 2026, disposing of 124,529 shares for total proceeds of $29,375,516.卡地纳健康(CAH)首席执行官Hollar Jason M.于2026年8月19日完成场内股票出售,合计减持124,529股,交易总价值29,375,516美元,相关Form 4备案文件于2026年8月20日提交至美国SEC。该笔交易的总价值占CAH当前550亿美元市值的0.053%,属于核心管理层的大额但非控股股东级别的持仓调整。
CAH earnings call: guidance, demand, margins, analyst Q&A卡地纳健康 (CAH) 电话会要点:指引、需求、利润率、分析师问答
Aaron Alt: In fiscal year '27, we expect at least $1 billion in share repurchases, which would be the third consecutive year of additional share repurchases above our original stated baseline commitment.2027财年,我们预计股票回购规模至少达到10亿美元,这将是连续第三年超出最初披露的基准承诺额度进行额外股票回购。
CAH earnings release — EPS beat +20.2% · revenue missed -2.3%卡地纳健康 (CAH) 财报发布 — EPS 高于预期+20.2% · 营收 低于预期-2.3%
Cardinal Health, Inc. reported EPS $2.91 vs $2.42 estimate and revenue $63.7B vs $65.2B estimate.卡地纳健康 公布财报:EPS $2.91 vs $2.42 预期,营收 $63.7B vs $65.2B 预期。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Distribution
Country
US
Exchange
—
Beta
0.53
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.